Immunovant, Inc. IMVT Ratios & Valuation
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -64.8%-2.4pp | -62.5%-9.5pp | -52.9%-2.2pp | -50.7%-14.3pp | |
| Liquidity | |||||
| Current ratio | 9.1×-2.1× | 11.2×-2.5× | 13.7×+4.4× | 9.3×-2.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $4.67+0.1% | $4.67+4.3% | $4.47+51.9% | $2.95-31.2% | |
| Valuation | |||||
| Market capitalization | $5.06B+74.2% | $2.9B-37.8% | $4.67B+131% | $2.02B+215% | |
| Price / book | 5.9×+1.8× | 4.1×-3.5× | 7.6×+2.0× | 5.6×+4.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immunovant, Inc.'s ratios come from?
- Every ratio is computed from Immunovant, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.